Zacks: Brokerages Expect Theravance Biopharma Inc (NASDAQ:TBPH) Will Post Earnings of -$1.06 Per Share

Brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post earnings of ($1.06) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.15) and the highest estimate coming in at ($1.01). Theravance Biopharma posted earnings per share of ($1.10) during the same quarter last year, which suggests a positive year-over-year growth rate of 3.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Theravance Biopharma will report full year earnings of ($4.34) per share for the current year, with EPS estimates ranging from ($4.65) to ($3.92). For the next year, analysts forecast that the company will report earnings of ($4.01) per share, with EPS estimates ranging from ($4.55) to ($3.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.50. The firm had revenue of $26.15 million for the quarter, compared to the consensus estimate of $13.92 million.

Several brokerages have commented on TBPH. BidaskClub lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Theravance Biopharma in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $44.25.

NASDAQ TBPH traded up $0.18 during trading on Friday, hitting $17.97. The company had a trading volume of 6,981 shares, compared to its average volume of 203,083. Theravance Biopharma has a one year low of $15.18 and a one year high of $31.26. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -4.50 and a beta of 1.64. The company’s fifty day moving average is $21.01 and its 200-day moving average is $20.21.

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Theravance Biopharma in the 1st quarter worth $156,000. CWM Advisors LLC bought a new position in shares of Theravance Biopharma in the 2nd quarter worth about $167,000. Wolverine Trading LLC bought a new position in shares of Theravance Biopharma in the 2nd quarter worth about $203,000. DekaBank Deutsche Girozentrale increased its stake in shares of Theravance Biopharma by 64.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 7,500 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Theravance Biopharma by 117.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 28,969 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 15,627 shares in the last quarter. Institutional investors and hedge funds own 84.16% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: Current Ratio

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.